Beckman Coulter

Rare Element Resources Announces Appointment of Ken Mushinski as President and Chief Executive Officer

Retrieved on: 
Monday, March 18, 2024
Energy, Natural Resources, Other Energy, Mining, Minerals, Mechanical engineering, Electronics, RER, Beckman Coulter, Bear, Interim, Plan, General Atomics, San Diego State University, Management

Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to announce the appointment of Ken Mushinski as its President and Chief Executive Officer.

Key Points: 
  • Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to announce the appointment of Ken Mushinski as its President and Chief Executive Officer.
  • Ms. Kelli Kast, a current Board member and consultant with nearly twelve years of service to the Company, has been appointed as the Interim President and Chief Executive Officer effective as of March 20, 2024.
  • Kelli Kast will serve as the Company’s Interim President and Chief Executive Officer during the period between the departure of Mr. Berg and the commencement of Mr. Mushinski’s tenure.
  • Rare Element Resources’ majority shareholder, Synchron, is an affiliate of General Atomics.

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Biometrics, Other Health, Health, Other Science, Science, Neurodegenerative disease, Fujirebio, DirectX, Partnership, Patient, Biomarker, RUO, IVD, Beckman Coulter, Apolipoprotein E, Therapy, Physician, AFL, Amyloid, Medical imaging

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics.
  • These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer.
  • Kevin O’Reilly, President, Beckman Coulter Diagnostics, commented, “We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream.”
    “Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

Rare Element Resources Announces Results of Oversubscribed Rights Offering of Common Shares

Retrieved on: 
Tuesday, March 12, 2024
Mining, Minerals, Natural Resources, Form, Electronics, Sale, News, Beckman Coulter, Prospectus, Bear, Engineering, Security (finance)

Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to report that its previously announced rights offering of common shares was oversubscribed and generated approximately US$35.8 million in gross proceeds.

Key Points: 
  • Rare Element Resources Ltd. (the “Company” or “RER”) (OTCQB: REEMF) is pleased to report that its previously announced rights offering of common shares was oversubscribed and generated approximately US$35.8 million in gross proceeds.
  • Preliminary results indicate that, pursuant to the rights offering, the Company will be issuing approximately 298.1 million common shares (including approximately 206.8 million common shares to be issued to holders who exercised their basic subscription privilege) at US$0.12 per share.
  • The Company will effectively be issuing all of the common shares that were available for subscription under the rights offering.
  • Following the issuance of new common shares pursuant to the rights offering, it is expected that Synchron will own approximately 70.6% of the issued and outstanding common shares of the Company.

Tom Oxley to Keynote 2024 Bioelectronic Medicine Forum in New York City

Retrieved on: 
Tuesday, March 19, 2024
General partnership, Patient, Beckman Coulter, Skin, MCRA, Litre, Mount Sinai Health System, Movement

NEW YORK, March 19, 2024 /PRNewswire/ -- Neurotech Reports , the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024.

Key Points: 
  • NEW YORK, March 19, 2024 /PRNewswire/ -- Neurotech Reports , the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024.
  • The keynote speaker at this year's event is Tom Oxley, CEO of Synchron and an interventional neurologist at Mount Sinai Health System.
  • For more information on the 2024 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html .
  • Photo caption: Tom Oxley, Ph.D., M.D., will keynote the 2024 Bioelectronic Medicine Forum on April 5, 2024 in New York City.

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024
Neurodegenerative disease, Health, Fujirebio, DirectX, Partnership, Patient, Biomarker, Research, RUO, IVD, Beckman Coulter, Apolipoprotein E, Analyser, Therapy, Physician, AFL, Amyloid

BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer's disease therapeutics.
  • Kevin O'Reilly, President, Beckman Coulter Diagnostics, commented, "We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream."
  • "Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world," stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. "We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide."

Element Biosciences Announces Senior Vice President of Global Sales and Support

Retrieved on: 
Tuesday, March 12, 2024
Genomics, Science, SAN, Support, Doctor of Philosophy, Beckman Coulter, Senior, Biology, Danaë, Airline

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support.

Key Points: 
  • Element welcomes Danae Van Oene, a proven genomics commercial leader, as the company expands its multi-omics capabilities
    SAN DIEGO, March 12, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support.
  • As Element expands its global customer base, she will work with Element customers and distributors internationally to maximize operational excellence and translate feedback into product innovations.
  • Danae was most recently 10x Genomics' Vice President and General Manager for the Americas region after previously leading its global sales programs, global distribution, and strategic partnerships.
  • Before joining 10x Genomics, she held global sales management roles at Illumina and was Distribution Territory Manager for Beckman Coulter.

Phizzle Launches Next Phase of Digital Air at Pittcon; Company adds Beckman Coulter APCs to Industry-Leading Platform

Retrieved on: 
Tuesday, February 27, 2024
FDA, Beckman Coulter, Automation, Telescopic sight

San Diego, California--(Newsfile Corp. - February 27, 2024) - In a Pharma industry first from the floor of Pittcon this week, Phizzle will remotely operate both a Beckman Coulter and a Climet air particle counter at the same time via a single user interface.

Key Points: 
  • San Diego, California--(Newsfile Corp. - February 27, 2024) - In a Pharma industry first from the floor of Pittcon this week, Phizzle will remotely operate both a Beckman Coulter and a Climet air particle counter at the same time via a single user interface.
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • Phizzle's EDGMaker is the world's first and only scientific instrument platform to centrally manage drug production data.
  • Our technology is unlocking the manufacturing potential of the pharmaceutical industry by bringing data standardization, instrument automation, and FDA-compliant digital record-keeping to critical drug production.

Parexel Appoints Susan R. Salka to Board of Directors

Retrieved on: 
Thursday, February 1, 2024
Beckman Coulter, Economics, Playtex, McKesson Corporation, Private equity, Chadron State College, Social, ChromeOS, Patient, Inclusion, EQT, Equity, AMN, San Diego State University, University, Goldman Sachs, Health

DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President of AMN Healthcare Services, Inc., to its Board of Directors.

Key Points: 
  • DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President of AMN Healthcare Services, Inc., to its Board of Directors.
  • Ms. Salka brings more than 30 years of healthcare leadership experience to Parexel, serving as AMN Healthcare’s Chief Executive Officer and President from 2005 to 2022, and as a director of the company from 2003 to 2022.
  • “We are thrilled to welcome Susan to the Parexel Board,” said Sheri McCoy, Chairperson of the Board.
  • "I am pleased and honored to join Parexel’s Board of Directors," said Susan Salka.

Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Retrieved on: 
Tuesday, January 30, 2024
Senior, Sigma, CLIA, QC, Beckman Coulter, Chemistry, Small Business Saturday, DXC, Medical device

DUBAI, UAE, Jan. 29, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories.

Key Points: 
  • DUBAI, UAE, Jan. 29, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024.
  • The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes."
  • The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks.
  • The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only.

Copan Colibrí™ Receives Third FDA Clearance, Further Expanding Automated ID/AST Workup Capabilities

Retrieved on: 
Tuesday, January 30, 2024
Medical microbiology, Artificial intelligence, Patient, Partnership, The central science, Workflow, Sensitivity and specificity, Microbiology, Beckman Coulter, Laboratory, FDA, Vision system, Use, Medical device

The automated ID/AST preparation instrument is a key component in Copan's full laboratory automation line that revolutionizes the workflow and efficiency of microbiology labs.

Key Points: 
  • The automated ID/AST preparation instrument is a key component in Copan's full laboratory automation line that revolutionizes the workflow and efficiency of microbiology labs.
  • The Colibrí™ system is a fully automated specimen preparation platform designed to prepare MALDI-TOF ID targets and create bacterial suspensions for Antibiotic Susceptibility Testing (AST).
  • The latest FDA clearance recognizes the ability of the Colibrí™ instrument to seamlessly integrate with the Beckman Coulter MicroScan Walkaway Instruments & Panels for ID/AST.
  • Later that year the Colibri™ system received FDA 510(k) clearance for use with bioMérieux VITEK® 2 Antimicrobial Susceptibility Testing System.